Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Equity (2022 - 2026)

Zentalis Pharmaceuticals has reported Return on Equity over the past 5 years, most recently at 0.01% for Q1 2026.

  • For Q1 2026, Return on Equity changed 0.0% year-over-year to 0.01%; the TTM value through Mar 2026 reached 0.01%, changed 0.0%, while the annual FY2025 figure was 0.0%, 0.0% changed from the prior year.
  • Return on Equity for Q1 2026 was 0.01% at Zentalis Pharmaceuticals, down from 0.01% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.0% in Q3 2022 and troughed at 0.01% in Q1 2025.
  • A 5-year average of 0.01% and a median of 0.01% in 2023 define the central range for Return on Equity.
  • On a YoY basis, Return on Equity climbed as much as 0bps in 2023 and fell as far as 0bps in 2023.
  • Year by year, Return on Equity stood at 0.01% in 2022, then decreased by -17bps to 0.01% in 2023, then grew by 20bps to 0.0% in 2024, then decreased by -22bps to 0.01% in 2025, then dropped by -7bps to 0.01% in 2026.
  • Business Quant data shows Return on Equity for ZNTL at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.